RV 144: The Thai Phase III Trial and Development of a Globally-Effective, Multi-Clade HIV Vaccine HIV Vaccine: Quo Vadis AIDS 2010 20 July 2010 Dr. Merlin.

Slides:



Advertisements
Similar presentations
Pox-Protein Public-Private Partnership (P5)
Advertisements

1 Workshop on the immunological basis of vaccine efficacy Vaccine and Infectious Disease Institute December 14, 2009 Ira M. Longini, Jr. Center for Statistical.
Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID July 2, 2013 HIV Vaccine and Future Strategies.
State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.
ANIMAL MODELS HIV Cure Research Training Curriculum The HIV CURE training curriculum is a collaborative project aimed at making HIV cure research science.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Prof. Fatma Amer Medical Microbiology and Immunology, ZAGAZIG FACULTY OF Medicine, Egypt President of ISC/HWG President of ArAPUA In the Era of Direct.
HIV-VACCINES. HIV - Vaccines  Vaccine development remains priority of AIDS research   Best hope for protection against HIV infection.
What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology.
BLOOD BORNE PATHOGEN EXPOSURE Management – What you need to know about Needlesticks and Splashes Amy J. Behrman, MD Occupational Medicine Dept of Emergency.
Immune Strategies for HIV Prevention
Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.
AVAC Global Advocacy for HIV Prevention AIDS Vaccines: The basics May 2015.
Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.
CBER Perspective VRBPAC Meeting, November 16, 2010.
Introducing Apceden™.
Update: Lowering Measles Antibody Lot Release Specification in IGIV/IGSC Blood Products Advisory Committee May 1, 2008 Dorothy Scott, M.D. Division of.
How HIV affects the Immune System. INTRODUCTION HIV attacks and kills crucial immune system cells, known as T-helper cells. Without T-helper cells many.
HIV Vaccine Research & Development
Novel strategies for prevention and treatment of HIV infection Prasit Faipenkhong Pairoaj Vonghathaipaisarn Rodjana Chunhabundit Zhang Jianjun.
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.
Dr Hannah Kibuuka Makerere University Walter Reed Project Presentation at the Uganda Medical Association-Uganda Veterinary Association joint conference.
Potential Cost-Effectiveness of a Tuberculosis Vaccine: Implications for Clinical Trials Jared Ditkowsky Kevin Schwartzman MD, MPH Montreal Chest Institute,
The Influence of CCL3L1 Gene- Containing Segmental Duplications on HIV-1/AIDS Susceptibility Gonzalez et al. Mar 4, 2005 :307 Science Presenter: Braydon.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.
The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.
Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
Prophylatic vaccine replacing conventional BCG Delphine Noël Vanessa Infante Surendra Karki.
Lab of Immunoregulation Berkower Lab Weiss Lab -- Angelo Spadaccini -- Russell Vassell -- Yisheng Ni -- Yong He -- Yisheng Ni -- Yong He –Hong Chen --
Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,
1 Resistance and Tropism - Maraviroc Lisa K. Naeger, Ph.D. Division of Antiviral Products Food and Drug Administration April 24, 2007 FDA Antiviral Advisory.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
Effects of Vaccines Thomas D. Overbay, DVM Expedite.
AIDS Vaccines: the basics CindraFeuer AVAC: Global Advocacy for HIV Prevention 20 April 2010 The HIV Research Catalyst Forum Baltimore, Maryland April.
VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.
John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Five: Immunology, Assay Standardization,
Vaccines and Related Biological Products Advisory Committee Meeting Hepatitis B Vaccine (Recombinant), Adjuvanted (HEPLISAV): Review of Immunogenicity.
Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.
Human clinical trial of DNA-MVA HIV vaccine candidate begins A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.
25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.
VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE ALVAC-vCP1521 plus AIDSVAX B/E CRF01_AE (Clade E) -based HIV vaccines Phase 3 Trial in Thailand.
1 Assessment of the Effectiveness of Small Pox Vaccines: Immunogenicity Assay Considerations Freyja Lynn Division of Bacterial, Parasitic and Allergenic.
CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.
$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.
Herpes Simplex Virus Type 2 infection among U.S. military service members: Public Health Implications and Opportunities for HIV Prevention Christian T.
MHRP  The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.
Adaptive trial designs in HIV vaccine clinical trials Morenike Ukpong Obafemi Awolowo University Ile-Ife, Nigeria.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.
04/19/ Projected effectiveness of mass HIV vaccination with multi-dose regimens to be tested in South Africa Peter Gilbert Dobromir Dimitrov Christian.
SAFETY AND EFFICACY OF MVA85A, A NEW TUBERCULOSIS VACCINE, IN INFANTS PREVIOUSLY VACCINATED WITH BCG: A RANDOMISED, PLACEBO-CONTROLLED PHASE 2B TRIAL Michele.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Methods of Infection Prevention in Advanced HIV Care Francesca Conradie President of the Southern African HIV Clinicians Society.
HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK
RV305 ADCC Update 10-February-2016 G. Ferrari.
Principles of HPV vaccination Some derived from Phase III trials Some are based on clinical judgement / research HPV vaccines have no contraindications.
Scientific Challenges for the Development of an HIV Vaccine
Maternal Toxicity Management
HIV Vaccine Trials Network
? Neutralizing Antibodies: Research pathways in 2013 and beyond
Epidemiological Modeling to Guide Efficacy Study Design Evaluating Vaccines to Prevent Emerging Diseases An Vandebosch, PhD Joint Statistical meetings,
Volume 155, Issue 3, Pages (October 2013)
Understanding Vaccine Partial Efficacy
Presentation transcript:

RV 144: The Thai Phase III Trial and Development of a Globally-Effective, Multi-Clade HIV Vaccine HIV Vaccine: Quo Vadis AIDS July 2010 Dr. Merlin Robb Deputy Director, Clinical Research US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research

Objectives  Overview of RV144 outcomes Post-hoc hypothesis generating analyses  Update on ongoing research efforts Correlates research  Product development plans for a globally-effective HIV vaccine 7 June MHRP

6-month vaccination schedule 3 years of follow-up (every 6 mo.) ALVAC®-HIV (vCP1521) priming at week 0, 4, 12, 24 AIDSVAX® B/E gp120 boosting at week 12, 24 (time in years) HIV test, risk assessment and counseling Vaccination and Follow-up Schedule RV 144

Vaccine Efficacy Appears Highest 6-12 months mITTPP monthEventsEfficacyEventsEfficacy 61654%n/a %2168% %4141% %5327% %6231% 12 months = 60% (Cox PH, 95% CI 22, 80) 3.5 years after first vaccination: Protective Efficacy = 31.2% P = % CI: 1.1 – 52.1% No effect on viral load RV 144

Anti-gp120 Reciprocal Mean Geometric Titers 1 VISIT 2 WEEKS POST VACCINE (V8) 24 WEEKS POST VACCINE (V9) AFRIMSVRC AFRIMSVRCAFRIMSVRC FOLD DECREASE (8:9 – A) FOLD DECREASE (8:9- V) ANTIGEN A MN Courtesy of Dr. Rick Koup, May 2010

Baseline Risk-stratified Treatment Effects (mITT) VaccinePlaceboTreatment Effect NEndpointsPY Rate %NEndpointsPY Rate %Efficacy95% CI Low3, , % -8.5, 67.2 Medium2, , % -6.0, 74.0 High1, , % -72.7, 46.3 VE for each risk category was statistically similar Caveats: Overall incidence was low Risk was primarily heterosexual in low prevalence setting 90% of infections subtype E RV 144

Baseline versus cumulative risk Risk AssessmentRisk : Treatment Interaction Baseline risk (pre-hoc analysis)p = 0.21 “Ever” high / not ever highp = This may reflect the transient protective effect of the vaccine regimen rather than imply protection only in “lower risk” individuals RV 144

RV 144 lessons  Protection from infection possible No or minimal primary neutralizing antibody Limited CD8 T cell immunity Other immune effectors play a role  Protection seems greatest early and in low risk participants Boosting may improve overall efficacy Studies must consider risk variable  Mode of transmission  Frequency of exposure  Dose per exposure 8 7 June 2010 RV 144

Ongoing RV 144 Research  November 2009 Immunogenicity studies HIV virus characterization  May 2010: Correlates Pilot Studies begin Collaboration with 30 US and international researchers Using RV144 samples  Humoral and Innate Immunity  T-cell immunity  Host Genetics  Animal Models 9 7 June 2010 RV 144

Goal: Globally Effective HIV Vaccine 10 Effective in high-risk populations Multi-clade protection against acquisition Durable, safe and effective Globally accessible GLOBALLY EFFECTIVE HIV VACCINE Corollary: Efficacy trials are the only way to determine a correlate of immunity and establish a rational basis for HIV vaccine development. MHRP

Vaccine Strategy: Guiding Principles  Reasonable concepts Distinct from those previously tested, and Best represent the concept  Evaluate these in efficient efficacy trials Leverage a diversity of approaches Build incrementally on past successes Minimize risk 11 7 June 2010 MHRP

Product Development Plan Parallel product development pathways toward a globally effective HIV vaccine. REGIONAL VACCINE STRATEGY Building on the RV144 regimen Phase IIb efficacy trial with extended ALVAC/protein boosts, shorter follow-up: a)MSM Thai population b)High-risk heterosexuals in RSA APPROACH BUILDING ON RV144 1 Multi-clade populations for study Increase CD8 potency Improve humoral response Add primary neutralizing AB APPROACH 7 June 2010 DIVERSIFYING AND REFINING THE PORTFOLIO GLOBAL VACCINE STRATEGY Pursuing diverse approaches toward a globally effective vaccine. 2 MHRP

Vaccine Downselection  A known correlate (unlikely) would guide downselection  In the absence of a correlate: If products generate similar immune responses, strongest response will be selected If products generate distinct immune response, both concepts should be considered  Practical considerations inform selection: Availability, complexity, and cost 13 7 June 2010 MHRP

A Balanced Strategy 14 7 June 2010 BUILDING ON RV144: A Regional Vaccine Strategy 1 DIVERSIFYING AND REFINING THE PORTFOLIO: A Global Vaccine Strategy Objective: minimize risk and maximize the likelihood of achieving an effective HIV vaccine. MHRP 2